Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
February 14 2008 - 8:30AM
PR Newswire (US)
BOSTON, Feb. 14 /PRNewswire/ -- Scimitar Equity Research, Inc.
(Scimitar) issues a review of Neurobiological Technologies, Inc.
(NASDAQ:NTII), entitled, "When You Review Stroke Treatments, Look
at One Stroke Drug at a Time; Each One is Different". This review
is available at our website: http://www.scimitarequity.com/.
Neurobiological Technologies, Inc. (NTII) is a biotechnology
company engaged in the business of acquiring and developing central
nervous system related drug candidates. NTII is a specialty
biopharmaceutical company with expertise in identifying and
acquiring promising drug candidates and in designing and managing
late-stage clinical trials for central nervous system conditions.
Neurobiological Technologies, Inc is currently developing
Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal
Phase 3 trials for the treatment of acute ischemic stroke. For
further information, please visit NTII's website at
http://www.ntii.com/. Scimitar Equity Research, Inc provides
sponsored equity research of emerging healthcare companies for the
investing communities. We certify that all the views expressed in
this review, accurately reflect our personal views about NTII
(NASDAQ) and its or their securities. No part of our compensation
was, is, or will be, directly or indirectly, related to the
specific recommendations or views contained in this review and we
will not have any investment banking relationships or personal
investment in any sponsored company. Investors are advised that
this analysis and review is issued solely for informational
purposes and is not to be construed as an offer to sell or the
solicitation of an offer to buy. Scimitar was paid for preparing
this review. This analysis and review does not have regard to the
specific investment objectives, financial situation and the
information contained herein is based on sources that we believe to
be reliable but is not guaranteed by us as being accurate and does
not purport to be a complete statement or summary of the available
data. Any opinions expressed are statements of our own judgment as
of the date of publication and are subject to change without
notice. Please read all our important disclosures. CONTACT:
Scimitar Equity Research, Inc. Henry W. McCusker Director of
Research phone: (617) 559.1080 fax: (617) 559.1083 e-mail:
DATASOURCE: Scimitar Equity Research, Inc. CONTACT: Henry W.
McCusker, Director of Research of Scimitar Equity Research, Inc.,
+1-617-559-1080, Fax: +1-617-559-1083, Web site:
http://www.scimitarequity.com/ http://www.ntii.com/
Copyright
Neurobiological (NASDAQ:NTII)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neurobiological (NASDAQ:NTII)
Historical Stock Chart
From Sep 2023 to Sep 2024